Moleac
Moleac is a Singapore-based biopharmaceutical company founded in 2003 that develops and markets NeuroAiD II, an oral herbal treatment for post-stroke recovery and brain injury rehabilitation, sold direct-to-consumer and via exclusive distributors in 30+ countries.
- Company typePrivate
- Founded2003
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Moleac does
Moleac is a privately held Singapore-based biopharmaceutical company founded in 2003 that develops and commercializes a single core product, NeuroAiD (marketed in its updated form as NeuroAiD II), an oral treatment derived from a proprietary complex herbal formulation. The product is positioned as the world's first post-stroke recovery treatment, designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence by amplifying endogenous brain repair processes; it is also positioned to support cognitive function in Alzheimer's Disease. Its clinical and manufacturing credentials rest on more than 90 peer-reviewed publications and a Gold accreditation from the independent nonprofit Empowered By Evidence (EBE) awarded in February 2026.
The company generates revenue through two channels: direct-to-consumer e-commerce sales via moleac.com (payment via PayPal, credit card, or wire transfer, with international shipping from Singapore) and exclusive country-level distribution partnerships with local pharmaceutical companies that handle in-market sales and HCP engagement. NeuroAiD is available in over 30 countries, with recent expansion activity in Mongolia (via Monos Group, May 2026) and active commercial efforts across Indonesia, Vietnam, Taiwan, and broader Southeast Asia.
Moleac's go-to-market emphasizes healthcare professional engagement through sponsored symposia at major neurology conferences (e.g., ESOC 2026 in Maastricht), hosted summits (Neurological Disorders Summit in Da Nang, Neurovascular Summit in Taipei), and ongoing collaboration with stroke-focused physician networks such as the Asian Stroke Advisory Panel (ASAP). The firm employs 11-50 people, is founder/management-owned with no disclosed institutional investors, and operates as Moleac Pte Ltd from its headquarters at Helios, Biopolis Way, Singapore.
Moleac firmographics
Firmographics- Name
- Moleac
- Legal name
- Moleac Pte Ltd
- Website
- https://moleac.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Moleac is a Singapore-based biopharmaceutical company founded in 2003 that develops and markets NeuroAiD II, an oral herbal treatment for post-stroke recovery and brain injury rehabilitation, sold direct-to-consumer and via exclusive distributors in 30+ countries.
- Ownership category
- akta.pro rank
Moleac industry classification
Industry- Product category
- Neurorehabilitation Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Moleac is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
Moleac business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Product Sales (NeuroAiD/NeuroAiDII): Direct-to-consumer sales through the company's e-commerce website (moleac.com) with products shipped internationally from Singapore. Sales are processed through PayPal or credit card for online orders, with wire transfer available for phone/email enquiries.
- International Distribution Partnerships: Products distributed through exclusive partnership agreements with local pharmaceutical companies in various countries (e.g., Monos Group in Mongolia, PT Ferron Par Pharmaceuticals in Indonesia), expanding market reach globally.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Moleac product offering
Product offeringCore offering
Moleac develops and commercializes NeuroAiD/NeuroAiD II, an oral natural pharmacological treatment designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence. The product is also indicated to support cognitive function in Alzheimer's Disease, and is sold directly via the company's e-commerce website and through exclusive pharmaceutical distribution partners across 30+ countries.
Product overview
Moleac is a biopharmaceutical company focused on neurology, offering a single core product: NeuroAiD II (also marketed as NeuroAiD). This is an oral pharmacological treatment designed to help patients recover functional independence after stroke or traumatic brain injury by amplifying endogenous processes of brain repair. The company also provides educational content about neurological conditions including stroke, TBI, and Alzheimer's disease, along with a stroke recovery coach tool. Product is developed with scientific excellence and evidence-based approach, with over 90 publications supporting the formulation.
Differentiator
Problem solved
Functional benefit
Brands
- NeuroAiD: The world's first post-stroke recovery treatment, an oral treatment helping patients of brain and spinal cord injuries who suffer from established deficits to recover their functional independence in addition to rehabilitation therapy and exercises. Also supports cognitive functions in Alzheimer's Disease.
- NeuroAiD II
Products and services
- NeuroAiD II NeuroAiD II is an oral treatment for patients of brain and spinal cord injuries who suffer from established deficits, designed to help them recover functional independence in addition to rehabilitation therapy and exercises. It also supports cognitive functions in Alzheimer's Disease. The product amplifies endogenous processes of brain repair and is available in over 30 countries worldwide.
Quantifiable outcome
- Over 90 scientific publications supporting the product's efficacy and safety
- +2 more outcomes
Companies that use Moleac
Customer profileSegments3 records
Ideal customer profiles3 records
Moleac technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Moleac partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Monos GroupcoreMonos Group is Mongolia's leading healthcare and pharmaceutical company, founded in 1990 and recognized for its innovation, research, and nationwide impact. Partnered with Moleac for the successful launch of NeuroAiD™II in Mongolia, committed to advancing clinical knowledge in neurorehabilitation and improving neurological recovery outcomes for patients in Mongolia.
- PT Ferron Par PharmaceuticalscorePT Ferron Par Pharmaceuticals collaborated with Moleac to host a Neurovascular Summit in Taipei, focusing on brain injury management. The meeting brought together healthcare professionals from across Indonesia for valuable exchange and collaboration to improve patient outcomes.
- Asian Stroke Advisory Panel (ASAP)coreMoleac is proud to support ASAP's mission to advance acute stroke management and remains committed to fostering impactful conversations and the sharing of knowledge. ASAP is a panel uniting leaders in neurology across Asia to push the boundaries of stroke care.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Moleac competitors and assessment
Company assessmentDirect peers
- NoNO Inc. Developer of nerinetide and other neuroprotection therapies for acute ischemic stroke, comparable to Moleac as a specialty neurology company addressing stroke treatment gaps.
- Athersys: Developed MultiStem cell therapy for ischemic stroke and other neurological indications, directly comparable as a small-cap company targeting the post-stroke recovery space.
- DiaMedica Therapeutics: Clinical-stage biopharmaceutical company developing treatments for stroke and other neurological conditions, directly comparable to Moleac's focus on post-stroke recovery therapeutics.
- ReNeuron: Cell therapy developer focused on stroke disability and other neurological conditions, comparable to Moleac in targeting post-stroke functional recovery.
- Genervon Biopharmaceuticals: Clinical-stage biotech developing GM604 and related multi-target peptides for ALS, stroke, and other neurological conditions, comparable to Moleac in pursuing novel therapeutics for CNS indications.
Broad incumbents
- Boehringer Ingelheim: Global pharmaceutical company with Actilyse (alteplase) for acute ischemic stroke, representing an established incumbent in stroke therapeutics and a benchmark for clinical credibility in the space.
- Daiichi Sankyo: Major Japanese pharmaceutical company with neurology portfolio and strong Asia-Pacific presence, comparable to Moleac in its regional commercialization footprint and neurological focus.
- Biogen: Large multinational biopharmaceutical company with a broad neurology franchise spanning multiple sclerosis, Alzheimer's, and stroke-related conditions, serving as a major incumbent competitor in CNS therapeutics.
Regional players
- Yiling Pharmaceutical: Leading Chinese traditional Chinese medicine (TCM) pharmaceutical company, comparable to Moleac as a botanical/herbal-based pharmaceutical with neurology-related indications, primarily operating in the China market.
- Pharmascience (Korea): Korean specialty pharmaceutical company with neurology and rehabilitation product portfolio, comparable to Moleac in pursuing neurology therapeutics in Asian markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Moleac social profiles
Digital presenceMoleac compliance and trust
Trust signalCompliance1 record
Moleac financial estimates
Financial estimateRevenue estimate
Valuation estimate
Moleac leadership team
Management profileNumber of profiles
Profiles3 records
Moleac funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Moleac M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Moleac
What does Moleac do?
Moleac develops and commercializes NeuroAiD/NeuroAiD II, an oral natural pharmacological treatment designed to help patients with established neurological deficits from stroke, traumatic brain injury, or spinal cord injury recover functional independence. The product is also indicated to support cognitive function in Alzheimer's Disease, and is sold directly via the company's e-commerce website and through exclusive pharmaceutical distribution partners across 30+ countries.
Is Moleac a public or private company?
Moleac is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Moleac founded?
Moleac was founded in 2003. It employs 11 to 50 people.
Where is Moleac based?
Moleac is headquartered in Singapore, Singapore, in the Asia region.
How does Moleac make money?
Two revenue lines are on record. Product Sales (NeuroAiD/NeuroAiDII) is the primary driver. The others are international Distribution Partnerships.
Who are Moleac's main competitors?
Direct peers on record are NoNO Inc., Athersys, DiaMedica Therapeutics, ReNeuron and Genervon Biopharmaceuticals. Broad incumbents are Boehringer Ingelheim, Daiichi Sankyo and Biogen. Regional players are Yiling Pharmaceutical and Pharmascience (Korea).
Does Moleac have an API?
No public API is recorded for Moleac.
What industry is Moleac in?
Moleac's product category is Neurorehabilitation Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.